Biote Forecasts Over $175M Revenue Despite Decline
The company's third-quarter 2026 revenue fell 9.6% after a January recall delayed clinic onboarding and procedure volume.
Updated on Nov. 16, 2026 in Corporate Finance

Live Poll
Would you pay for a hormone-therapy clinic visit at current prices?
Biote reported third-quarter 2026 revenue of $43.3 million, down 9.6% year over year, during its November 4, 2026 earnings call. The company announced full-year 2026 revenue guidance above $175 million.
Why it matters
The decline followed a January 2026 voluntary product recall that delayed new clinic onboarding and clinical procedure volume, while temporary reliance on third-party suppliers pushed gross margin down to 67.7%. The guidance signals management's expectation that clinic attrition can be reduced and procedure volume rebuilt.
Biote's third-quarter 2026 revenue was $43.3 million, a 9.6% year-over-year decline, with gross margin at 67.7% after temporary reliance on third-party suppliers. Full-year 2026 revenue guidance is above $175 million, though the filing material does not detail how the second half will close the gap.
The players
biote
A publicly traded company that provides hormone optimization therapy through a network of clinics and reports its results to investors.
Xteria Health
A supplier whose production has returned to pre-recall levels and which now provides over half of biote's shipped pellets.
The details
Revenue contracted after a voluntary product recall in January 2026 delayed new clinic onboarding and clinical procedure volume. Xteria Health has returned to pre-recall production levels and now supplies over 50% of shipped pellets, up from 30% in the second quarter, while management uses data analytics to identify clinics needing support and directs field representatives toward lagging clinics.
Timeline
January 2026: Voluntary product recall delays clinic onboarding and procedures.
Second quarter 2026: Xteria Health supplies 30% of shipped pellets.
November 4, 2026: Third-quarter 2026 earnings call held.
Corporate Finance Context
The third-quarter decline follows the company's January 2026 voluntary product recall, which created a lagged drag on clinic onboarding and procedure volume that the new guidance now seeks to reverse. Management's push to convert clinic relationships into consistent procedure volume reflects a recovery effort that will be judged against the recall-driven slowdown.
Investors weighing biote's stock should compare the $175 million full-year guidance against the $43.3 million quarterly run rate to judge whether the second half must accelerate sharply. Shareholders face near-term uncertainty until clinic attrition falls and procedure volume recovers.
The takeaway
A company's recovery from an operational shock depends less on headline guidance than on whether it can convert existing customer relationships into steady volume. Tracking clinic retention and procedure counts in upcoming reports will show whether the guidance is credible.
Further reading
For broader context on how companies rebuild after setbacks, see Corporate Finance coverage.
Source note: This article includes information reported by The Motley Fool.
Live Poll
Would you pay for a hormone-therapy clinic visit at current prices?









